The committee will discuss biologics license application (BLA) 761143, teprotumumab solution for intravenous use, submitted by Horizon Pharma Ireland, Ltd., proposed for the treatment of active thyroid eye disease.
Back to All Events
Earlier Event: December 10
Cardiovascular and Renal Drugs Advisory Committee
Later Event: December 17
Oncologic Drugs Advisory Committee